The label moved. The coverage policy didn’t.
On June 9, 2023 the FDA expanded Inspire’s labeling: the BMI ceiling rose from 32 to 40 and the AHI ceiling from 65 to 100.1 But Medicare’s governing local coverage determination — L38276, “Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea” — still requires BMI under 35 and an AHI of 15–65.2 As of early 2024, no MAC had adopted the expanded indications, and most commercial plans still capped coverage at BMI 32–35.3
So a patient can be squarely FDA-eligible and still policy-ineligible. That isn’t a clinical disagreement — it’s a documentation problem hiding as a clinical one, and it’s appealable when the chart is built to the policy rather than to the label. For the broader pattern across this specialty, see our overview of sleep-medicine denials.
BMI 40
FDA-cleared ceiling since June 2023
Inspire / FDA
BMI 35
Medicare LCD coverage ceiling
CMS L38276
AHI 65
Medicare ceiling vs FDA’s 100
CMS L38276
What a covered UAS claim actually has to prove.
Coverage of hypoglossal nerve stimulation (CPT 64582 implant; 64583 revision; 64584 removal) turns on a short, specific evidence set. Miss one element and the denial writes itself:2
Confirmed — e.g., machine-derived usage under 4 hr/night for ≥70% of nights, despite optimized interface and settings.
Drug-induced sleep endoscopy confirming the absence of complete concentric collapse at the soft-palate level — the single most-cited contraindication.
15–65 for Medicare, on a polysomnogram within the look-back window.
Central plus mixed apneas under 25% of total AHI.
BMI under the payer’s cap, and age ≥22.
The verdict, restatedSleep medicine · UAS
A UAS denial is rarely a verdict on the surgery. It’s a verdict on whether the DISE finding and the CPAP-usage data are in the file, in the payer’s language.
Six ways an Inspire claim gets denied — and the usual fix.
Nearly every UAS denial reduces to one of six bases, and each has a documented answer. The appeal is the same evidence set, rearranged to the reason on the remittance.
| Denial basis | The usual fix in the appeal |
|---|---|
| “Investigational / experimental” | Cite the AAO-HNS position statement + FDA clearance (see §4) |
| BMI above the payer’s cap | Document BMI to the covered policy; appeal the label-vs-policy gap where applicable |
| AHI outside the covered band | Supply the qualifying PSG within the look-back window |
| CPAP failure not documented | Attach machine-derived adherence data showing failure/intolerance |
| DISE missing or non-confirmatory | Provide the DISE report confirming no complete concentric collapse |
| Central / mixed apneas too high | Show central+mixed <25% of total AHI on the study |
DISE = drug-induced sleep endoscopy. Coverage criteria above reflect Medicare LCD L38276; commercial policies (Aetna, Centene, Molina and others) track closely but vary by plan.
“Investigational” is the softest denial of all.
When a plan still calls upper-airway stimulation experimental, it is arguing against its own specialty society. The American Academy of Otolaryngology–Head and Neck Surgery’s position statement is direct:
Cited authority — verbatimAAO-HNS
Upper airway stimulation via the hypoglossal nerve is “a safe and effective second-line treatment of moderate to severe obstructive sleep apnea in patients who are intolerant or unable to achieve benefit with positive pressure therapy.”AAO-HNS position statement6
Paired with the device’s FDA clearance, that single citation converts most “investigational” denials into a documentation conversation — which is a conversation you win. It is a recurring finding in our review of what reviewers actually read: the named specialty-society authority outweighs the boilerplate.
The denials you don’t appeal are the ones you lose.
The population is large and the failure mode that sends patients to UAS is common: roughly half of CPAP patients are non-adherent (reported range 29–83%).4 Yet across Medicare Advantage in 2024, only 11.5% of denials were appealed — while 80.7% of the appeals that were filed got overturned.5 Device and surgical denials are not the exception to that pattern; they’re the heart of it. A UAS implant is high-dollar enough that a single un-appealed denial is real money — and structured enough that the appeal is the same five elements, every time.
~50%
of CPAP patients non-adherent
UpToDate (range 29–83%)
11.5%
of MA denials appealed, 2024
KFF · 2024
80.7%
of those appeals overturned
KFF · 2024
Build the appeal to the policy, not the label — automatically.
Merits Appeals turns a UAS denial into a ready-to-send, payer-specific appeal in minutes: it answers the exact denial reason, assembles the medical-necessity argument against the governing LCD or commercial policy, and pulls the DISE finding, the CPAP-adherence data, and the qualifying PSG into the rebuttal — every clinical quote verified verbatim against the chart.
Your team reviews and signs. Every time.
The point isn’t winning the appeals you already file. It’s making each one cheap enough to file all of them — the DISE, the adherence data, and the qualifying study, arranged into the payer’s own criteria, with each clinical claim traced to a named source.
Unsupported claims surface as review flags before the letter can leave. The provider attests and signs under their own name. The letter never mentions Merits or AI.